EXPLORE THE SCIENCE
TL;DR: A 2026 study in Psychopharmacology found that low oral THC doses did not meaningfully reduce most subjective or physiological responses when healthy adults retrieved memories of a prior social stress task. Key Findings Low-dose THC groups: Participants…
Read article
TL;DR: A 2026 study in Neuropsychopharmacology Reports found that repeated cigarette smoking and quitting shifted clozapine metabolism in one Japanese man with treatment-resistant schizophrenia, with the dose-adjusted clozapine level falling during smoking per…
Read article
TL;DR: A 2026 paper in Neuropsychopharmacology argued that cannabidiol (CBD), a non-intoxicating cannabis compound, has plausible psychiatric and neurological uses, but clinical claims need standardized products, exposure tracking, and safety monitoring before…
Read article
TL;DR: A 2026 study in Psychopharmacology found that healthy adults who used cannabis frequently had higher circulating THC markers after at least 12 hours of verified abstinence, but their cold-pressor pain threshold, pain tolerance, and pain ratings did not…
Read article
TL;DR: A 2026 placebo-controlled study in Human Psychopharmacology: Clinical and Experimental found that ebselen did not meaningfully reduce motor impulsivity, reflection impulsivity, delay discounting, or emotion-recognition outcomes in 130 healthy adults. Ke…
Read article
TL;DR: A 2026 study in Psychopharmacology found that after 14 days of unpredictable chronic stress, a single 1-hour ayahuasca exposure restored sociability, reduced anxiety-like behavior, normalized cortisol, and rescued whole-brain BDNF in adult zebrafish wit…
Read article